TipRanks
Santen Pharmaceutical Co Ltd (SNPHY)
OTHER OTC:SNPHY
US Market
SNPHY
Santen Pharmaceutical Co
RESEARCH TOOLSreports
Want to see SNPHY full AI Analyst Report?

Santen Pharmaceutical Co (SNPHY) Income Statement

5 Followers

Santen Pharmaceutical Co Income Statement

Last quarter (Q1 2026), Santen Pharmaceutical Co's total revenue was ¥68.74B, a decrease of -9.99% from the same quarter last year. In Q1, Santen Pharmaceutical Co's net income was ¥5.88B. See Santen Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 26Mar 25Mar 24Mar 23
Total Revenue
¥ 300.00B¥ 309.21B¥ 301.96B¥ 279.04B¥ 266.26B
Gross Profit
¥ 171.03B¥ 170.68B¥ 178.71B¥ 166.09B¥ 156.59B
Operating Expenses
¥ 124.15B¥ 122.74B¥ 140.17B¥ 169.18B¥ 120.70B
Depreciation and Amortization
¥ 8.81B¥ 19.47B¥ 18.18B¥ 17.25B¥ 17.05B
EBITDA
¥ 59.01B¥ 67.41B¥ 50.72B¥ 12.95B¥ 52.93B
Operating Income
¥ 46.88B¥ 47.94B¥ 38.54B¥ -3.09B¥ 35.89B
Other Income/Expenses
¥ 601.00M¥ 2.36B¥ -8.67B¥ -2.71B¥ -270.00M
Pretax Income
¥ 47.48B¥ 50.30B¥ 29.87B¥ -5.80B¥ 35.62B
Net Income
¥ 36.26B¥ 39.62B¥ 26.64B¥ -14.95B¥ 27.22B
Per Share Metrics
Basic EPS
¥ 103.98¥ 121.43¥ 72.62¥ -38.58¥ 68.07
Diluted EPS
¥ 103.68¥ 121.43¥ 72.37¥ -38.58¥ 67.97
Weighted Average Shares Outstanding
 348.61M 327.62M 366.89M 387.42M 399.77M
Weighted Average Shares Outstanding (Diluted)
 349.69M 328.37M 368.14M 387.42M 400.46M
Currency in JPY

Santen Pharmaceutical Co Earnings and Revenue History